A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

Fludarabine, cyclophosphamide, and rituximab (FCR) is highly effective initial therapy for younger patients with chronic lymphocytic leukemia (CLL); however, most eventually relapse. Duvelisib is a delta/gamma PI3K inhibitor approved for relapsed/refractory CLL. We conducted an investigator-initiate...

Descripción completa

Detalles Bibliográficos
Autores principales: Davids, Matthew S., Fisher, David C., Tyekucheva, Svitlana, McDonough, Mikaela, Hanna, John, Lee, Brandon, Francoeur, Karen, Montegaard, Josie, Odejide, Oreofe, Armand, Philippe, Arnason, Jon, Brown, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895867/
https://www.ncbi.nlm.nih.gov/pubmed/32820271
http://dx.doi.org/10.1038/s41375-020-01010-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895867/
https://www.ncbi.nlm.nih.gov/pubmed/32820271
http://dx.doi.org/10.1038/s41375-020-01010-6

Ejemplares similares